Related Experiment Videos
Intravenous pulse methylprednisolone in chronic idiopathic thrombocytopenia
Archives of Disease in Childhood
|August 1, 1984
Insights
Two children with chronic idiopathic thrombocytopenic purpura achieved remission after receiving pulsed intravenous methylprednisolone therapy. This treatment offers a potential new option for refractory cases of this autoimmune bleeding disorder.
Area of Science:
- Pediatric Hematology
- Immunology
- Pharmacology
Background:
- Chronic idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts.
- Standard treatments like corticosteroids and intravenous immunoglobulin (IVIG) are not always effective.
Observation:
- Two pediatric patients with chronic ITP were unresponsive to conventional therapies.
- These patients received a novel treatment regimen.
Findings:
- Pulsed intravenous methylprednisolone (15 mg/kg/day for three consecutive days) was administered.
- Both children achieved a positive clinical response and maintained remission for at least three months.
Implications:
- Pulsed methylprednisolone may be an effective alternative for children with refractory chronic ITP.
- Further research is warranted to confirm efficacy and safety in a larger cohort.
Abstract:
Two children with chronic idiopathic thrombocytopenic purpura unresponsive to either standard corticosteroid treatment or high dose intravenous gammaglobulin, or both, were treated with intravenous methylprednisolone (15 mg/kg/day) given in pulses over three consecutive days. Both children showed a positive response and are still in remission after three months.